ACD Seminar Series
RNAscope® Technology
 

February 28th, 2017

Max Planck Institute of Experimental Medicine, Goettingen

Complete this form to register


RNASCOPE® TECHNOLOGY 

February 28, 2017 

01:00 - 03:00 PM

The Max Planck Institute of Experimental Medicine
- Seminar room A1- 
Hermann-Rein-Straße 3
37075 Göttingen


 

RNAscope® technology is being routinely used for tissue-based gene expression analysis for target validation, pathobiology and biomarker development in every disease area. This technology, with its capacity to provide single-cell and single-RNA molecule sensitivity in the context of complex tissue microenvironments, is an ideal tool to complement technologies like IHC, qPCR or NGS.

Our recent advances in RNAscope® technology, now enables detection of any mRNA, short RNA targets and exon junctions. In this seminar we will discuss how RNA ISH has been successfully applied to various areas of research and will highlight the benefits of RNAscope® technology.

 

Our Senior Director of Scientific Affairs, Dr. Emily Park, will present the application of RNAscope® and BaseScope™ in Neuroscience research and will give an overview on:

  • Detection, characterization, and (co-)localization of mRNAs in the central and peripheral nervous system
  • Validation of target mRNA expression
  • Validation of (cell type-specific) genetic modifications
  • Detection of mRNA in the nervous system when no (reliable) antibodies are available
  • Detection of long non-coding RNA (lncRNA)
  • Visualization of neuronal activity and plasticity markers

 

In addition, Dr. Liane Wüstefeld, Institute of Clinical Neuroscience at the Max Planck Institute of Experimental Medicine, Göttingen will give a presentation: "First experience with RNAscope®" 

We would also like to extend this invitation to your colleagues and other scientists in your organization who are using molecular methods for gene expression analysis and are interested in new RNA technologies.


Speaker

Dr. Liane Wüstefeld,
Institute of Clinical Neuroscience at the Max Planck Institute of Experimental Medicine, Göttingen

Dr. Emily Park, Senior Director of Scientific Affairs 
Advanced Cell Diagnostics, Inc.